GLP-1 Peptides for Weight Loss: How They Work, Who Qualifies, and What to Expect

GLP-1 peptides are prescription medicines that mimic glucagon-like peptide-1 to reduce appetite, slow stomach emptying, and improve insulin response after meals. FDA-approved weight-loss options include semaglutide as Wegovy and liraglutide as Saxenda; tirzepatide as Zepbound is a dual GLP-1/GIP medicine. Trials show average losses near 8% to 21%, with side effects and eligibility limits. [1][2][3][4]

What are GLP-1 peptides, and how are they different from peptide therapy?

GLP-1 peptides are prescription medications that act like glucagon-like peptide-1, a hormone your gut releases after eating. For weight loss, the main FDA-labeled options are semaglutide, liraglutide, and tirzepatide, and FDA status differs by brand. [7][8][9]

GLP-1 receptor agonists vs. wellness peptides

Semaglutide (Wegovy, Ozempic; a GLP-1 receptor agonist; also available as compounded semaglutide through some licensed 503A pharmacies) is FDA-approved as Wegovy for chronic weight management in certain adults and adolescents. Ozempic is FDA-approved for type 2 diabetes and selected cardiovascular and kidney risk uses in adults with type 2 diabetes, not for weight loss alone. [7][10]

Tirzepatide (Zepbound, Mounjaro; a dual GLP-1/GIP receptor agonist; also available as compounded tirzepatide through some licensed 503A pharmacies) is FDA-approved as Zepbound for chronic weight management in certain adults and for obstructive sleep apnea in certain adults with obesity. Mounjaro is FDA-approved for type 2 diabetes, not for weight loss alone. [8][11]

Liraglutide (Saxenda, Victoza; a GLP-1 receptor agonist) is FDA-approved as Saxenda for chronic weight management in certain adults and adolescents. Victoza is FDA-approved for type 2 diabetes, not for weight loss alone. [9][12]

Wellness peptides are different. CJC-1295, BPC-157, and MOTS-c are discussed in some peptide therapy settings, but they are not FDA-approved for weight loss. Some have been studied for body composition, tissue repair, or metabolic health in early or non-weight-loss research, but that is not the same as an FDA-approved obesity medication. [5][6]

Why GLP-1s are FDA-approved medications, not supplements

FDA-approved GLP-1 medications have been studied for specific uses, with labels that list approved indications, dose schedules, side effects, warnings, and contraindications. Supplements do not go through the same FDA approval process for safety and effectiveness before marketing. [5][7][8][9]

How do GLP-1 peptides cause weight loss?

GLP-1 medicines may support weight loss through linked pathways: appetite signals in the brain, slower stomach emptying, and glucose-dependent insulin release after meals. These same effects help explain why gastrointestinal side effects like nausea, vomiting, diarrhea, constipation, and reflux are common. [1][2][3][7]

Appetite regulation in the hypothalamus

GLP-1 receptors are found in brain areas involved in hunger and fullness, including pathways that communicate with the hypothalamus. Activating these pathways can lower appetite for some people, but low appetite can also lead to under-eating, nausea, or low fluid intake if not monitored. [1][13]

Slowed gastric emptying and satiety

GLP-1 medicines can slow how quickly food leaves the stomach. This may help people feel full sooner, but it can also raise the risk of reflux, bloating, constipation, vomiting, and problems in people with severe stomach-emptying disorders. [1][7][8][9]

Insulin sensitivity and blood sugar effects

GLP-1 receptor agonists increase insulin release when glucose is high and reduce glucagon release. This is one reason some GLP-1 medicines are FDA-approved for type 2 diabetes, but people using insulin or sulfonylureas may have a higher risk of low blood sugar and need medical supervision. [1][7][8][10]

Which GLP-1 peptide is best for weight loss?

The “best” choice depends on your diagnosis, side effects, contraindications, access, insurance, and goals. Tirzepatide produced greater average weight loss than semaglutide in a major head-to-head trial, but both medicines can cause gastrointestinal side effects and have boxed warnings; there is no single best option for everyone. [14][7][8]

Semaglutide — brand and compounded

Semaglutide is a GLP-1 receptor agonist. Wegovy is FDA-approved for chronic weight management in certain adults and adolescents, and Ozempic is FDA-approved for type 2 diabetes and selected cardiovascular and kidney risk uses in adults with type 2 diabetes, not for weight loss alone. The FDA-approved Wegovy label lists 0.25 mg once weekly as the initial dose, with escalation to a maintenance dose of 1.7 mg or 2.4 mg once weekly when clinically appropriate. [7][10]

In STEP 1, participants received semaglutide 2.4 mg once weekly plus lifestyle support and lost 14.9% of body weight on average at 68 weeks, compared with 2.4% with placebo; nausea, diarrhea, vomiting, and constipation were common. Individual results vary. [2]

Compounded semaglutide may be prepared by a state-licensed 503A pharmacy when legal requirements are met and a clinician writes a patient-specific prescription. Compounded semaglutide is not an FDA-approved product, and FDA does not review compounded drugs for safety, effectiveness, or quality before dispensing. [5]

Tirzepatide — dual GLP-1/GIP

Tirzepatide is a dual GLP-1/GIP receptor agonist. Zepbound is FDA-approved for chronic weight management in certain adults and for obstructive sleep apnea in certain adults with obesity; Mounjaro is FDA-approved for type 2 diabetes, not for weight loss alone. The FDA-approved Zepbound label lists 2.5 mg once weekly as the starting dose, with labeled maintenance doses of 5 mg, 10 mg, or 15 mg once weekly. [8][11]

In SURMOUNT-1, participants received tirzepatide 5 mg, 10 mg, or 15 mg once weekly plus lifestyle support and lost 15.0% to 20.9% of body weight on average at 72 weeks, compared with 3.1% with placebo; nausea, diarrhea, constipation, and vomiting were common. Individual results vary. [3]

Compounded tirzepatide is not an FDA-approved product. If used, it should come from a properly licensed pharmacy and be prescribed only after clinician review of risks such as pancreatitis history, gallbladder disease, pregnancy plans, kidney issues, and other medications. [5][8]

Liraglutide — daily option

Liraglutide is a GLP-1 receptor agonist. Saxenda is FDA-approved for chronic weight management in certain adults and adolescents. The FDA-approved Saxenda label lists 0.6 mg once daily as the initial dose, with weekly escalation to 3 mg once daily when clinically appropriate. [9]

In a 56-week randomized trial, participants received liraglutide 3.0 mg once daily plus lifestyle support and lost 8.0% of body weight on average, compared with 2.6% with placebo; nausea, vomiting, diarrhea, and constipation were common. Individual results vary. [4]

How much weight can you lose on a GLP-1, and how fast?

GLP-1 results vary. In trials, weight loss built over months, not days. Average losses ranged from about 8% with liraglutide at 56 weeks to about 15% with semaglutide at 68 weeks and about 21% with tirzepatide at 72 weeks; side effects and stopping rates were part of the same trial picture. [2][3][4]

First 3 months: typical trajectory

Some people notice appetite changes before major scale changes. The first 3 months often include label-based dose escalation, side-effect adjustment, and nutrition changes under clinician direction. Clinicians watch for nausea, vomiting, constipation, dehydration, low blood sugar risk in people using certain diabetes medicines, and signs that the medication is not a safe fit. [7][8][9]

12-month trial data

In STEP 1, adults without diabetes received semaglutide 2.4 mg once weekly plus lifestyle support and lost 14.9% of body weight on average at 68 weeks, compared with 2.4% with placebo. Gastrointestinal events were common, and some participants stopped because of side effects. [2]

In SURMOUNT-1, adults without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly plus lifestyle support and lost 15.0% to 20.9% on average at 72 weeks, compared with 3.1% with placebo. Gastrointestinal events were the most common side effects and were usually mild to moderate during dose escalation. [3]

In a major liraglutide trial, adults without diabetes received liraglutide 3.0 mg once daily plus lifestyle support and lost 8.0% on average at 56 weeks, compared with 2.6% with placebo. Nausea and other gastrointestinal side effects were more common with liraglutide than placebo. [4]

What affects your individual results

• Starting weight, metabolic health, sleep, stress, and activity level.
• Protein intake and resistance training, which may help protect lean mass during weight loss. [15][16]
• Medication tolerance and whether side effects limit nutrition or hydration.
• Other medicines, including insulin or sulfonylureas, which may require closer monitoring for low blood sugar. [7][8][9]
• Access, cost, follow-up, and whether the treatment plan can be maintained.

Who qualifies for a GLP-1 for weight loss?

Eligibility is based on BMI, related health conditions, age, pregnancy status, medication history, and safety risks. FDA weight-management labels generally include adults with obesity or adults with overweight plus at least 1 weight-related condition, but a clinician must decide if a GLP-1 is appropriate. [7][8][9]

BMI thresholds and comorbidities

Wegovy and Zepbound labels include chronic weight management for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. Examples include hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease depending on the label. Saxenda has a similar adult weight-management BMI framework. [7][8][9]

Some adolescents may qualify for specific FDA-approved options under pediatric label criteria. This requires careful clinician review, growth and development monitoring, and family-centered support. [7][9]

Who should not take a GLP-1

GLP-1 and GLP-1/GIP medication labels carry a boxed warning about thyroid C-cell tumors. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. These medicines are also not recommended during pregnancy, and labels advise stopping before planned pregnancy according to the product’s guidance. [7][8][9]

A clinician should also review pancreatitis history, gallbladder disease, severe gastrointestinal disease, kidney problems related to dehydration risk, diabetic retinopathy history for some semaglutide users, and drugs that can cause low blood sugar. [7][8][9][10]

What are the side effects of GLP-1 peptides?

Side effects are common, especially during dose escalation. The same mechanisms that support fullness and blood sugar control can also cause nausea, constipation, diarrhea, reflux, abdominal pain, and vomiting; rare but serious risks require prompt medical review. [1][7][8][9]

Common GI side effects and titration

In major trials and drug labels, gastrointestinal symptoms were the most common side effects. FDA labels use gradual dose-escalation schedules to improve tolerability, but specific dose changes should be made only by a licensed clinician. [2][3][7][8][9]

• Nausea may be worse with large, greasy, or very sweet meals.
• Constipation can happen when food intake, fluid intake, or movement drops.
• Vomiting or diarrhea can lead to dehydration and kidney strain, especially in people with kidney disease or those taking diuretics. [7][8][9]
• Reflux and bloating may occur because gastric emptying slows. [1]

Muscle loss and how to protect lean mass

Weight loss can include both fat mass and lean mass. Clinical trials show GLP-1 medicines can reduce body weight, but preserving muscle usually requires enough protein, resistance training, sleep, and follow-up; people who under-eat because of nausea may be at higher risk of losing lean mass. [15][16]

Rare but serious risks

Labels warn about pancreatitis, gallbladder disease, acute kidney injury related to dehydration, serious allergic reactions, increased heart rate for some agents, suicidal thoughts or behavior monitoring for weight-management products, and possible worsening diabetic retinopathy with semaglutide in some patients with type 2 diabetes. [7][8][9][10]

What happens when you stop taking a GLP-1?

Stopping a GLP-1 often leads to some weight regain because appetite and metabolic signals can shift back. In an extension of the STEP 1 trial, participants regained about two-thirds of prior weight loss within 1 year after stopping semaglutide, even after earlier lifestyle support. [17]

Weight regain data

The STEP 1 extension found that cardiometabolic improvements also moved back toward baseline after semaglutide withdrawal. This does not mean the medication failed; it shows that obesity is often a chronic condition that may need long-term care, balanced against side effects, cost, access, and patient preference. [17]

Maintenance strategies

Maintenance plans may include nutrition support, resistance training, sleep care, stress management, ongoing medication for some people, or a clinician-guided transition plan when stopping is appropriate. No one should stop or restart a prescription medication without clinician guidance. [7][8][9][17]

How do you get a GLP-1 prescription: brand vs. compounded, and where does Chia fit in?

Getting a GLP-1 starts with a medical evaluation, not a product choice. Brand-name and compounded options differ in FDA approval, insurance coverage, pharmacy process, and cost; a licensed clinician should review BMI, labs, medications, contraindications, and side-effect risk before prescribing. [5][7][8][9]

Brand-name access and insurance

Brand-name GLP-1 prescriptions may be filled through retail or mail-order pharmacies if approved by insurance or paid out of pocket. Coverage often depends on diagnosis, plan rules, prior authorization, and whether the prescribed brand is FDA-approved for the intended use. [7][8][9]

Compounded semaglutide and tirzepatide via 503A pharmacies

A 503A compounding pharmacy can prepare a patient-specific medication from bulk drug substances or approved drugs when legal requirements are met and a licensed clinician writes a prescription. Compounded semaglutide and compounded tirzepatide are not FDA-approved products, and FDA does not verify their safety, effectiveness, or quality before they are dispensed. [5]

Chia is one telehealth option where a licensed clinician can evaluate eligibility for compounded GLP-1 treatment and longevity peptides when appropriate, using partner 503A pharmacies and safety review steps; it is not the only path, and the right option depends on your clinical history and local availability.

What should you know before starting a GLP-1?

Before starting, it helps to know that GLP-1 treatment is usually a months-long plan with follow-up, not a quick fix. Trial results are averages over 56 to 72 weeks, and benefits must be balanced with side effects, contraindications, cost, access, and lifestyle support. [2][3][4][7][8][9]

Protein, resistance training, and hydration

Lower appetite can make it harder to eat enough protein or drink enough fluids. Resistance training and adequate protein may help preserve lean mass during weight loss, while hydration and fiber may help with constipation; a clinician or dietitian can tailor this safely. [15][16]

Realistic expectations and follow-up

• Appetite changes may happen early, but weight loss usually builds over time.
• Side effects are common and should be discussed before they become severe.
• Plateaus can happen and do not always mean the medication stopped working.
• Medication choice may change if side effects, supply, insurance, or health goals change.
• Individual results vary, and no medication guarantees a specific amount of weight loss.

Frequently asked questions

Keep reading

Weight Loss

Peptide Injections for Weight Loss: What Actually Works

GLP-1 Weight Loss

How to Get Weight-Loss Injections Online: A Step-by-Step Guide

GLP-1 Weight Loss

How to Get a GLP-1 Prescription Online: What to Expect, Who Qualifies, and What It Costs